Phase II Study of FOLFOX + Erbitux as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type

Trial Profile

Phase II Study of FOLFOX + Erbitux as first Line therapy in metastatic colorectal cancer with EGFR-detectable and KRAS wild type

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Levofolinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jan 2017 Results of a sub analysis of JACCRO CC-05 and JACCRO CC-06 trials presented at the 2017 Gastrointestinal Cancers Symposium
    • 15 Jun 2016 Results published in the Targeted Oncology
    • 15 Jun 2016 Status changed from recruiting to completed as result published in Targeted oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top